Favorece la curacin, potencia la funcin inmunolgica y mejora el bienestar general gracias a sus propiedades teraputicas nicas
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
About the Author: Dr Birgit Schiel, life and social counselling (focus on health), individual diploma studies in health science specialist area: pharmacy, doctorate degree in natural sciences, scientific consultant at Pro Medico
Patients with type 2 diabetes Semaglutide was originally developed for type 2 diabetes management before its weight loss benefits became the primary use case
p.Ile316Met) of MET, affecting a highly conserved residue in the SEMA domain ( A study on Caucasian population patients with schizophrenia showed a genetic association between the pathology and MET SNP variants ( HGF gene in schizophrenia